In 2012 UBC CPD received the Royal College Accredited CPD Provider Innovation Award for This Changed My Practice.
By Shirley Jiang, Edward Tam, and Hin Hin Ko on August 4, 2021
Primary biliary cholangitis (PBC) is the most common autoimmune liver disease with an incidence of 1 in 1000 in women over age 40. For decades, the only evidence-based treatment was ursodeoxycholic acid. Unfortunately, the rate of inadequate response to UDCA is up to 40%. In 2017, Health Canada approved the use of obeticholic acid (OCA) for the treatment of PBC. UDCA remains first-line therapy for PBC with a long record of use and generic preparations but in non-responders, OCA treatment should be considered.
By Trana Hussaini Pharm D and Eric M. Yoshida MD FRCPC on November 13, 2019
For the first time, since the identification of hepatitis C virus, the goal of HCV elimination is a tangible and achievable target mainly due to the availability of highly efficacious and well tolerated DAA regimens.
By Dr. Paul Mullins on October 26, 2016
Alcoholic hepatitis (AH), perhaps more accurately described as alcohol-related cholestatic liver failure, is a clinical syndrome with high mortality. In severe AH at 28 days: 30-40%. STOPAH is a UK multi-centre, double-blind, randomized trial in severe AH to assess the effect of Prednisolone and/or Pentoxifylline on mortality at 28 days, and mortality or liver transplantation at 90 days and at one year.
By Dr. Eric Yoshida on July 18, 2011
This year, based on the phase III studies published in the New England Journal of Medicine, the FDA approved the new protease inhibitors, telapravir and boceprevir in combination with pegIFN and ribavirin for patients with HCV G1 infections.